Loading organizations...

§ Private Profile · Santa Clara, CA, USA
Shape Memory Medical is a technology company.
Shape Memory Medical develops innovative smart polymer technologies for medical applications, focusing on enhancing clinical outcomes through advanced embolization solutions.
Shape Memory Medical has raised $52.0M across 2 funding rounds.
Shape Memory Medical has raised $52.0M in total across 2 funding rounds.
Shape Memory Medical has raised $52.0M across 2 funding rounds. Most recently, it raised $38.0M Series C in March 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2024 | $38M Series C | Earlybird Venture Capital | Atlantic Bridge, Borski Fund, Seroba Life Sciences, Emergent Medical Partners, HBM Healthcare Investments, HBM Medfocus, WexMed II | Announced |
| Jul 25, 2017 | $14M Series B | HBM Healthcare Investments | Emergent Medical Partners, HBM Medfocus, Wexford Capital | Announced |
Shape Memory Medical has raised $52.0M in total across 2 funding rounds.
Shape Memory Medical's investors include Earlybird Venture Capital, Atlantic Bridge, Borski Fund, Seroba Life Sciences, Emergent Medical Partners, HBM Healthcare Investments, HBM-MedFocus, WexMed II, Wexford Capital.
Shape Memory Medical is a California-based medical device company specializing in innovative therapeutic solutions using proprietary shape memory polymer (SMP) technology for embolization in vascular markets.[1][2][6] It develops products like the IMPEDE Embolization Plug family, TrelliX Embolic Coil, and IMPEDE-FX RapidFill Device, which serve interventional radiologists, vascular surgeons, and neurointerventionalists treating conditions such as peripheral vascular issues, neurovascular aneurysms, and abdominal aortic aneurysms (AAA).[2][3][4][6] These devices solve key problems in traditional embolization—such as poor conformability, chronic inflammation, limited visibility, and recurrence—by promoting rapid clot formation, anatomical adaptation, bioabsorption, and radiolucent clarity for durable occlusion and healing.[1][2][6] The company has raised $38 million in Series C financing in 2023, supports ongoing pivotal trials like AAA-SHAPE, and has products approved in over 25 countries, signaling strong growth momentum in a high-CAGR neurovascular and aortic market.[2][4]
Shape Memory Medical traces its roots to research on shape memory polymers (SMPs) initiated at Lawrence Livermore National Laboratory (LLNL) and advanced at Texas A&M University, funded by the National Institutes of Health (NIH) and Department of Energy.[1][3] In 2009, Duncan Maitland, a key researcher from LLNL and Texas A&M, founded the company (initially as DEP Shape Memory Therapeutics) to commercialize SMPs for treating brain aneurysms and other vascular conditions, securing early funding from the Texas Emerging Technologies Fund, Research Valley Angel Fund, and millions in federal grants.[3] An exclusive licensing agreement with LLNL was finalized in 2010, leading to 12 issued patents and 15 pending ones, with market launches in Europe (2016) and the US (2017).[3] The company relocated to California, rebranded, and under leadership like President and CEO Ted Ruppel (joined later) and Meghan Reu (Director of Quality & Regulatory since 2016), achieved FDA clearance as the first SMP-based vascular device and recognition as one of the "40 Best University Startups 2017."[1][3][5] Pivotal moments include the first patient in the AAA-SHAPE Pivotal Trial and the $38M Series C round led by Earlybird Venture Capital.[2][4]
Shape Memory Medical's edge stems from its exclusive use of regenerative smart polymers, setting it apart in embolization:
These features enhance developer and clinician experience through procedural simplicity and superior outcomes, backed by preclinical/clinical data.[6]
Shape Memory Medical rides the wave of bioabsorbable and smart materials in medtech, disrupting the $1.5B neurovascular (20% CAGR) and $700M detachable coil markets dominated by metal-based devices with high recurrence rates.[3] Timing aligns with rising demand for minimally invasive endovascular therapies amid an aging population—35M worldwide with AAA, causing 150K-200K annual rupture deaths—and advances in NIH-funded polymer tech from academic labs.[1][3][4] Favorable market forces include regulatory successes (first SMP vascular clearance), investor confidence ($38M Series C), and trials proving sac management in EVAR procedures.[2][4] The company influences the ecosystem by pioneering SMP commercialization, lowering material costs ($10/lb), and enabling cross-specialty expansion, potentially redefining aneurysm treatment standards and inspiring polymer innovations in cardiovascular and beyond.[1][3]
Shape Memory Medical is poised to expand its SMP portfolio with AAA-SHAPE trial results validating IMPEDE-FX for aortic markets, alongside neurovascular and peripheral growth via new indications and global commercialization.[2][4] Trends like personalized medtech, bioresorbables, and AI-guided procedures will amplify its conformable, visible tech, while Series C funds fuel randomized studies and manufacturing scale.[4] Its influence could evolve from niche disruptor to category leader, reshaping clinical success in embolization as adoption grows in high-burden vascular diseases—echoing its mission to drive smart polymer advancement across specialties.[1][6]